Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition

Field	Value	Language
dc.contributor.author	Rogiers, Aljosja	en_AU
dc.contributor.author	da Silva, Ines Pires	en_AU
dc.contributor.author	Tentori, Chiara	en_AU
dc.contributor.author	Tondini, Carlo Alberto	en_AU
dc.contributor.author	Grimes, Joseph M	en_AU
dc.contributor.author	Trager, Megan H	en_AU
dc.contributor.author	Nahm, Sharon	en_AU
dc.contributor.author	Zubiri, Leyre	en_AU
dc.contributor.author	Manos, Michael	en_AU
dc.contributor.author	Bowling, Peter	en_AU
dc.contributor.author	Elkrief, Arielle	en_AU
dc.contributor.author	Papneja, Neha	en_AU
dc.contributor.author	Vitale, Maria Grazia	en_AU
dc.contributor.author	Rose, Apri	en_AU
dc.date.accessioned	2021-02-09T22:29:30Z
dc.date.available	2021-02-09T22:29:30Z
dc.date.issued	2021
dc.identifier.uri	https://hdl.handle.net/2123/24432
dc.description.abstract	BACKGROUND: Patients with cancer who are infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are more likely to develop severe illness and die compared with those without cancer. The impact of immune checkpoint inhibition (ICI) on t	en_AU
dc.language.iso	en	en_AU
dc.subject	COVID-19	en_AU
dc.subject	Coronavirus	en_AU
dc.title	Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition	en_AU
dc.type	Article	en_AU
dc.identifier.doi	10.1136/jitc-2020-001931

Associated file/s

There are no files associated with this item.